- Home
- Publications
- Publication Search
- Publication Details
Title
Hydroxychloroquine for Primary Progressive Multiple Sclerosis
Authors
Keywords
-
Journal
ANNALS OF NEUROLOGY
Volume 90, Issue 6, Pages 940-948
Publisher
Wiley
Online
2021-09-30
DOI
10.1002/ana.26239
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis
- (2021) Robert J. Fox et al. NEUROLOGY
- Repurposing Domperidone in Secondary Progressive Multiple Sclerosis
- (2021) Marcus W. Koch et al. NEUROLOGY
- Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
- (2020) Eva Schrezenmeier et al. Nature Reviews Rheumatology
- Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis
- (2020) Marcus Sucksdorff et al. BRAIN
- Positron emission tomography imaging in evaluation of MS pathology in vivo
- (2018) Heidi Högel et al. Multiple Sclerosis Journal
- Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
- (2017) Simon Faissner et al. Multiple Sclerosis Journal
- The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
- (2017) Peter Feys et al. Multiple Sclerosis Journal
- Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
- (2017) Robert W Motl et al. Multiple Sclerosis Journal
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic
- (2017) Simon Faissner et al. Nature Communications
- Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
- (2017) Simon Faissner et al. Multiple Sclerosis Journal
- The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
- (2017) Peter Feys et al. Multiple Sclerosis Journal
- Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
- (2017) Robert W Motl et al. Multiple Sclerosis Journal
- Rheumatoid arthritis
- (2016) Josef S Smolen et al. LANCET
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque
- (2015) Josa M. Frischer et al. ANNALS OF NEUROLOGY
- Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis
- (2015) Marcus W. Koch et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- The promise of futility trials in neurological diseases
- (2015) Marcus W. Koch et al. Nature Reviews Neurology
- Systemic lupus erythematosus
- (2014) Larissa Lisnevskaia et al. LANCET
- Screening for Inhibitors of Microglia to Reduce Neuroinflammation
- (2013) Shazia Samanani et al. CNS & Neurological Disorders-Drug Targets
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines
- (2011) A. Kuznik et al. JOURNAL OF IMMUNOLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- The relation between inflammation and neurodegeneration in multiple sclerosis brains
- (2009) Josa M. Frischer et al. BRAIN
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More